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The Relationship Between Metabolic Syndrome




The prevalence of obesity has increased dramatically in 
children and adolescents, in both  developed and developing
worlds, becoming an important medical problem. Many of the
outcomes of obesity have traditionally been viewed as problems
of adulthood. However, it has become clear that many of these
abnormalities may start in childhood and adolescence (1,2,3,4).  
Obesity affects cardiovascular parameters such as left 
ventricular (LV) mass and cardiac function as well as metabolic
parameters such as insulin levels and glucose tolerance (5). These
latter variables are directly associated with hypertension, although
the mechanism is not fully understood. Epidemiologic evidence
has shown that insulin resistance is an independent risk factor for
atherosclerosis and coronary heart disease and is also a major
cause of type 2 diabetes mellitus (T2DM) (6,7). Thus,  the insulin-
resistance syndrome may be considered the hallmark for the
development of both diabetes and cardiovascular disease (8). The
metabolic syndrome (MS) is a cluster of atherogenic risk factors
including abdominal obesity, hypertension, insulin resistance, 
dyslipidemia, and a proinflammatory as well as a prothrombotic
state (9,10). It has been previously reported that MS is related to
abnormal LV geometry and function in nondiabetic adults with a
high prevalence of obesity, and that increased blood pressure (BP)
is the MS component most strongly associated with markers of
pre-clinical cardiovascular disease even in the absence of 
traditionally defined hypertension (11,12).  
MS and T2DM prevalences among obese adolescents are
quite high in the urban area of Konya, a city in the central
Anatolian region of Turkey (1,13). In a previous study, we
found that the prevalence of MS was 27.2% among obese
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among the adolescents aged 12–18 years (37.6%) than
among obese children aged 7–11 years (20%) (1). To date,
limited information is available on whether the presence of
MS is associated with significant cardiac abnormalities in
obese children and adolescents, or whether the impact of
MS on cardiac phenotype is independent of the single 
components of the syndrome.  To our knowledge, there have
been no comprehensive studies regarding the relationship
between MS and LV mass index (LVMI) during childhood.
The aim of our study was to investigate the relation between
MS and LVMI in a population of obese children and 
adolescents with MS as well as the relationships between
other metabolic features with LVMI. 
Materials and Methods
208 obese children and adolescents (119 females and 89
males) were recruited from the group of  obese children 
attending the outpatient clinic of the Pediatric Endocrinology
Unit of Selcuk University Hospital in Konya, Turkey between
December 2006 and December 2008. Obese children were
included in the study if they were 7-17 years of age and had
BMI≥95th percentile for age and gender based on the standards
of the Centers for Disease Control and Prevention (14). 
The mean age of the patients was 11.9±2.7 years (range: 
7-17 years) and the mean body mass index (BMI) was 29.1±4.8
kg/m2.  The control subjects were recruited from a population
of nonobese healthy children and adolescents who presented
to the hospital for minor illnesses. The control group consisted
of 24 females and 26 males aged 6-17 years. Their mean age
was 11.4±2.9 years and their mean BMI was 17.4±2.7 kg/m2.
Blood samples from the control group were collected at the
time of their clinical evaluation. Children were excluded if they
had a major illness including T1DM or T2DM, took medications,
or had a condition known to influence body composition, insulin
action, or insulin secretion (e.g. glucocorticoid therapy, 
hypothyroidism, Cushing’s disease). All subjects were in good
health and had normal thyroid functions. The study was
approved by the local ethics committee of Selcuk University.
Signed informed consent was obtained from each subject over
12 years of age, and informed parental consent was also
obtained for all children regardless of age. Each child underwent
a complete physical examination, including anthropometric
measurements. Height was measured to the nearest 0.5 cm
on a standard height board and weight was determined to the
nearest 0.1 kg on a standard physician’s beam scale with the
subject dressed only in light underwear and no shoes. BMI was
calculated as weight (in kilograms) divided by height (in meters)
squared. BP was measured with a standard mercury 
sphygmomanometer after the subjects had rested at least 10
minutes. Waist circumference was measured at the level of the
umbilicus with the patient standing and breathing normally. Hip
circumference was measured at the level of the iliac crest.
Waist/hip and waist/height ratios were calculated from 
the waist and hip circumference measurements. Waist 
measurements were evaluated using the percentile curves for
waist circumference of healthy Turkish children aged 7-17 years
reported by Hatipoglu et al (15).  
Blood Samples and Oral Glucose Tolerance Test 
After a 3-day high-carbohydrate diet (300 g/d) and an
overnight fast, a standard oral glucose tolerance test (OGTT)
(1.92 g/kg or a maximum of 82.5 g of glucose) was performed
in all subjects in the study group.  The initial venous blood 
samples were taken in the morning between 07.30 and 09.30,
after the children had fasted overnight. Following this initial
sampling (0 minute), venous blood samples were obtained at
30, 60, 90, and 120 minutes  to measure plasma glucose 
and insulin levels. 
Venous blood samples were also obtained in the control
group following an overnight fast, but the control group was not
subjected to OGTT, for ethical reasons. 
After clotting, the serum was separated and immediately
analyzed. Glucose was determined by the glucose oxidase
method. Plasma concentrations of total cholesterol, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides, apolipoprotein A (Apo-A) and
apolipoprotein B (Apo-B) were measured using  routine 
enzymatic methods with Olympus 2700 Analyzer (Olympus
Diagnostica GmbH, Hamburg, Germany). Insulin levels were
measured by a chemiluminescence immunoassay (Immulite,
Diagnostic Products, Los Angeles, CA).  
Measurement of Insulin Sensitivity Check Indices 
Insulin indices were derived from fasting blood samples and
samples obtained during the OGTT. The homeostasis model
assessment of insulin resistance (HOMA-IR), quantitative
insulin-sensitivity check index (QUICK-I), and fasting glucose to
insulin ratio (FGIR) were derived as estimates of insulin 
resistance. FGIR was calculated as fasting glucose 
concentration (mg/dL) /fasting insulin concentration (μU/mL).
HOMA-IR was calculated as fasting insulin concentration
(μU/mL) x fasting glucose concentration (mmol/L)/22.5 (15).
QUICK-I was calculated as 1/ [(log fasting insulin concentration
(μU/mL) + log fasting glucose concentration (mg/dL)] (16,17).
The total plasma glucose response and insulin secretion were
evaluated from the area under the response curve (AUC) 
estimated by the trapezoid rule. 
Echocardiographic Measurements 
A Philips Sonos 5500 system with a 5 MHz transducer 
ultrasonic imager was used for echocardiographic 
assessments. Participants were examined in the left lateral
decubitus position and images were acquired at passive 
end-expiration to minimize global cardiac movement from 
standard parasternal long axis and apical planes, by the same
expert operator. The M-mode echocardiographic study of the
left ventricle was performed under 2D control. The ventricular
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end-diastolic and end-systolic dimensions were determined
from M-mode echocardiogram according to the American
Society of Echocardiography recommendations (18). The LVM
was calculated using the formula of Devereux et al (19) by the
following equation: LVM = 0.80 [1.04 x (interventricular septal
thickness + posterior wall thickness + end-diastolic diameter) 3
- (end-diastolic diameter)3] + 0.6. The LVMI was calculated as
LVM divided by the body surface area. 
Definitions 
Based on the MS criteria proposed by the International
Diabetes Federation (IDF), patients were diagnosed as having
MS  when their waist circumference was ≥90th and when at
least two of the following factors were present (20): (1) raised
concentration of triglycerides: ≥150 mg/dL (1.7 mmol/L) or
receiving specific treatment for high triglycerides; (2) reduced
concentration of HDL cholesterol: <40 mg/dL (1.03 mmol/L) 
or receiving specific treatment for this lipid abnormality; (3)
raised BP: 
Systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg or
receiving treatment for previously diagnosed hypertension; and
(4) raised fasting plasma glucose concentration 100 mg/dL (5.6
mmol/L) or known T2DM. 
The obese patients were divided into MS group (n=55) 
and non-MS (n=153) group according to the IDF consensus 
definition of MS in children and adolescents (20). 
Statistical Methods 
The data were expressed as means±SD. The Kolmogorov-
Smirnov test was applied separately for males and females to
check the normality of the variables. Differences in the means
of variables were evaluated using both parametric and 
nonparametric tests depending on the distribution of the 
variables. Any variables that were not normally distributed were
log transformed before data analysis. Statistical correlation was
assessed using the Pearson’s test (r). Separate relationships
between LVMI and insulin sensitivity indices (HOMA-IR, FGIR
and QUICK-I) were also examined after adjustment for age,
sex, BMI-SDS, systolic and diastolic BP, total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, Apo-A and Apo-B,
using general linear regression models (backward analysis).
Statistical significance was taken as p<0.05. All statistical 
analyses were performed using the Statistical Package for
Social Sciences (SPSS/Windows version 13.0, SPSS Inc.,
Chicago, IL). We performed a receiver operating characteristic
(ROC) curve analysis in the SPSS version 11.0 to obtain a ROC
plot and a complete sensitivity/specificity report. A ROC curve
is a graph that plots the true positive rate in function of the false
positive rate at different cut-off points. The results of 
ROC curve analysis displayed the average value of sensitivity
for all possible values of specificity and the average value of
specificity for all possible values of sensitivity. The cut-off
points, sensitivity and specificity calculations for indices have
been based on LVMI with ROC curve analysis.
Results 
The characteristics of the study population are shown in
Table 1. Both the obesity group and control group showed no
significant difference in terms of age. Subjects in the obese
group had a significantly higher BMI-SDS, systolic and diastolic
BP, waist/hip and waist/height ratios. As shown in Tables 2,
total cholesterol, LDL cholesterol, Apo-B and triglyceride levels
were significantly elevated in obese children, whereas the 
concentration of HDL cholesterol was only slightly lower than
that in the controls. The values of LVMI were significantly 
higher in the obese group than in controls (p=0.033). Obese
subjects had significantly elevated HOMA-IR compared to the
control group (p<0.001), whereas FGIR and QUICK-I 
measurements in obese children were significantly lower than
in the control group (p<0.001). 
The MS group had a significantly higher BMI, BMI-SDS,
systolic and diastolic BP, waist circumference (Tables 3), 
triglyceride levels, HOMA-IR, FGIR and fasting insulin levels
than the non-MS group (p<0.001), whereas HDL cholesterol and
Apo-A levels of children with MS were lower than those of 
non-MS group. The non-MS group had a significantly lower
QUICK-I than the control group (p<0.001). The values of LVMI
in the MS group were significantly higher than those in the 
non-MS group (p=0.014) (Table 4). 
Table 5 shows the correlations between LVMI and other
measurements in obese children. When LVMI was 
considered as a continuous variable in the whole population
of obese children, it was found to be positively correlated in 
univariate analysis with BMI-SDS (r=0.262, p<0.001), waist 
circumference (r=0.264,  p<0.001), systolic BP (r=0.443,
p<0.001) and diastolic BP (r=0.436, p<0.001), triglycerides
(r=0.399, p<0.001), fasting insulin levels (r=0.367, p<0.001),
HOMA-IR (r=0.341, p<0.001) and FGIR (r=0.351, p<0.001)
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Table 1. Clinical characteristics of the study population  (mean±SD)         
Obese children  Controls p-value
n (female/male)  208 (119/89) 50 (24/26) -
Age (years) 12.0±2.7 11.5±2.9 0.22
Weight (kg) 71.2±21.2 38.6±13.0 <0.001
Height (cm)  152.0±2.5 144.0±16.0 0.001
BMI (kg/m2) 29.2±4.8 17.5±2.8 <0.001
BMI-SDS 2.5±0.6 -0.6±1.1 <0.001
Systolic BP (mmHg)  117.8±15.0 105.9±12.1 <0.001
Diastolic BP (mmHg) 76.7±11.6 62.0±7.3 <0.001
Waist-hip ratio 0.9±0.7 0.8±0.6 <0.001
Waist-height ratio 0.6±0.6 0.4±0.5 <0.001
BMI: body mass index, BP: blood pressure, SDS: standard deviation scoreand negatively correlated with HDL cholesterol (r=-0.261,
p<0.001), Apo-A (r=-0.223,  p=0.015), QUICK-I (r=–0.278, 
p<0.001). There was no significant relationship between
LVMI and clinical and laboratory parameters in controls (data 
not shown). 
Table 5 also depicts the correlations between LVMI 
and other measurements in the MS group. When LVMI was
considered as a continuous variable in the whole population of
the MS group, it was found to be positively correlated in 
univariate analysis with height (r=0.278,  p=0.023), weight
(r=0.62, p=0.004), BMI-SDS (r=0.360, p=0.005), fasting insulin
level (r=0.325,  p=0.009), HOMA-IR (r=0.319,  p=0.010) and
FGIR (r=0.311,  p=0.013) and negatively correlated with 
QUICK-I (r=–0.331, p=0.008). 
In the regression analysis, BMI (β=0.397,  p=0.002) and
HOMA-IR (β=0.373, p=0.004) were positively correlated with
LVMI even after adjusting for age, sex, BMI-SDS, systolic
BP/diastolic BP, total cholesterol, triglycerides, LDL cholesterol
and HDL cholesterol as co-factors with the total variance
explained being 25.7% (Table 6), but QUICK-I and FGIR 
were not significantly correlated with LVMI.  When LVMI was
considered as a continuous variable in the whole population of
the non-MS group, it was found to be positively correlated in
univariate analysis with height (r=0.278,  p=0.023), weight
(r=0.62, p=0.004), BMI-SDS (r=0.360, p=0.005) and systolic BP
(r=0.213,  p=0.006) and negatively correlated with QUICK-I 
(r=-0.331, p=0.008). In the regression analysis, BMI (β=0.498,
p<0.001) was positively correlated with LVMI even after 
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Table 3. Demographic and clinical data of the two subsets with and 
without MS
MS group non-MS group p-value
n (female/male)  55 153 -
Age (years) 12.9±2.8              11.7±2.6            0.005
Weight (kg) 79.5±22.3            68.5±20.39         0.001
Height (cm)  157.0±14.0             150.0±15.5             0.005
BMI (kg/m2) 30.8±4.9             28.6±4.8             0.004
BMI-SDS 2.7±0.5               2.4±0.6              0.001
Systolic BP (mmHg)  29.3±16.3          113.7±12.1           <0.001
Diastolic BP (mmHg) 84.5±13.2            73.9±9.6             <0.001
Waist-hip ratio 0.9±0.8                 0.9±0.7              0.92
Waist-height ratio 0.6±0.6                  0.6±0.6             0.163
BP: blood pressure, BMI: body mass index, MS: metabolic syndrome, SDS: standard
deviation score
Table 4. Laboratory findings of the two subsets with and without MS
Lipids MS group non-MS group p-value
Total cholesterol (mg/dL) 171.2±44.6          169.4±36.8           0.8
Triglyceride (mg/dL)  151.4±9                 89.4±46.0 <0.001
LDL cholesterol (mg/dL) 104.1±39.8          103.9±35.0           1.0
HDL cholesterol (mg/dL)  39.3±11.7             47.1±9.7           <0.001
Apo-A(mg/dL)  114.5±20.5           127.3±29.01 0.023
Apo-B (mg/dL) 86.8±22.1             82.6±22.0            0.3
Fasting  glucose (mg/dL)  88.6±12.5             89.5±13.2           0.7
Fasting  insulin (μU/mL) 26.0±13.9             16.9±9.0            <0.001
FGIR 3.4±0.9               5.3±1.5           <0.001
HOMA-IR  5.9±4.0                 3.7±2.0            <0.001
QUICK-I 0.3±0.2                 0.3±0.4            <0.001
O OG GT TT T   d de er ri iv ve ed d   i in nd di ic ce es s
AUC glucose (mg/dLx120 min) 13615±16 13571±13 0.9
AUC insulin (μU/mL x120 min) 11311±35 11186±34 0.8  
LVMI (g/m2) 66.16±17.48 59.15±17.3 0.014
HOMA-IR: homeostasis model assessment of insulin resistance, QUICK-I: quantitative
insulin sensitivity check index, FGIR: fasting glucose insulin ratio, OGTT: oral glucose
tolerance test, LVMI: left ventricular mass index, MS: metabolic syndrome, AUC: area
under the curve, LDL: low-density lipoprotein, HDL: high-density lipoprotein, VLDL: very
low-density lipoprotein 
Table 2. Laboratory findings of the study population (mean±SD)          
Lipids Obese children  Controls p-value
Total cholesterol (mg/dL) 170.0±39.0 157.1±36.3 0.39
Triglyceride (mg/dL)  105.85±66.2 79.6±43.6 0.001
LDL cholesterol (mg/dL) 103.9±36.2 93.1±31.6 0.040
HDL cholesterol (mg/dL)  45.0±10.8 48.0±13.9 0.103
VLDL cholesterol (mg/dL) 20.6±12.2 15.2±8.3 0.003
Apo-A(mg/dL) 124.1±27.6 121.6±21.9 0.575
Apo-B (mg/dL) 83.6±22.1 67.9±19.5 <0.001
Fasting  glucose (mg/dL)  89.3±13.0 91.5±10.1 0.212
Fasting  insulin  (μU/mL) 19.3±11.3 8.7±6.1 <0.001
FGIR 4.6±1.2 10.5±1.7 <0.001
HOMA-IR 4.3±2.8 2.0±1.5 <0.001
QUICK-I 0.3±0.3 0.4±0.5 <0.001
O OG GT TT T   d de er ri iv ve ed d   i in nd di ic ce es s
AUC glucose (mg/dLx120 min) 13582±1407 - -
AUC insulin (μU/mLx120 min)  11220±3482 - -
LVMI (g/m2) 61.10±17.61 55.92±14.30 0.033
HOMA-IR: homeostasis model assessment of insulin resistance, QUICK-I: quantitative
insulin sensitivity check index, FGIR: fasting glucose insulin ratio, OGTT: oral glucose
tolerance test, LVMI: left ventricular mass index, AUC: area under the curve, LDL: low-
density lipoprotein, HDL: high-density lipoprotein, VLDL: very low-density lipoprotein adjusting for age, sex, BMI-SDS, systolic BP/diastolic BP, total
cholesterol, triglycerides, LDL cholesterol and HDL cholesterol
as co-factors with the total variance explained being 15.7%, but
HOMA-IR, QUICK-I and FGIR were not significantly correlated
with LVMI (data not shown). 
The cut-off point for MS, along with sensitivity and 
specificity values, is demonstrated in Figure 1. The present
LVMI cut-off point of 33 g/m2 for the diagnosis of MS yielded a
sensitivity of 97% and a specificity of 98%.
Discussion
In this study, we compared the LVMI between 
obese patients and control subjects, and between patients
within the obese group with MS and without MS, using
echocardiographic measurements. In this study, we also 
evaluated the effect of insulin resistance on LVMI in both obese
children and children with MS.  
Obesity is associated with a group of metabolic 
abnormalities (e.g., dyslipidemia, insulin resistance, 
hyperglycemia, and hypertension) referred to as the MS. It has
been suggested that the metabolic abnormalities could be
involved in the modulation of LV structure. Several studies have
investigated the relationship between insulin resistance and LV
mass in both obese and hypertensive subjects with varying
results (11,12,13). Some studies found a relation between
insulin resistance and LVM (21,22), whereas others found no
relation at all after adjusting for covariates. In the present study,
the number of risk factors identified in both obese patients and
those with MS was associated with increased LVMI. We
observed that subjects with MS, diagnosed in accordance with
the IDF consensus definition of MS in children and adolescents,
exhibited higher LVMI values than subjects without MS.
Moreover, the relationship between MS and LVM was 
confirmed in linear regression models including MS together
with its individual components, as independent variables; this
suggests that MS may have a harmful effect on myocardial
structure over and above the potential contribution of each 
single component of this syndrome, above all body size and BP,
well-known independent determinants of LVM (22). 
Childhood obesity is a strong predictor of adult adiposity and
is associated with increased levels of LVM, which is viewed as
an important cardiovascular risk factor (23). Previous studies
performed in adolescents and young adults have shown a
strong association between BMI and high levels of LV mass,
independent of systolic BP (24). 
The association of MS with cardiac hypertrophy might 
be explained also by nonhaemodynamic factors, such as 
insulin resistance and the accompanying compensatory 
hyperinsulinemia, which are considered to be the major 
pathophysiological features underlying the MS (25). Trophic
effects of insulin on myocardial tissue have been demonstrated
in cell cultures and animal models and could be mediated, 
at least in part, by the insulin-like growth factor-1 (IGF-1)
receptors (26,27).  
A more central deposition of fat (i.e. android type) has been
shown to be associated with increased triglycerides, decreased
HDL cholesterol, increased systolic BP, and increased LVM in
adolescents. In our study, the univariate analysis demonstrated
that the LVMI was significantly associated with insulin 
sensitivity indices derived from fasting samples.   Moreover,
fasting insulin was significantly associated with LVMI in 
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Table 6. Variables independently associated, in an age-, sex-, and other
risk factor-adjusted backward multiple linear regression analysis, with
the dependent variable LVMI in patients with MS
LVMI
r2 β p
BMI 0.257 0.397      0.002
HOMA-IR 0.373 0.004
BMI: body mass index, HOMA-IR: homeostasis model assessment of insulin 
resistance, LVMI: left ventricular mass index, MS: metabolic syndrome 
Table 5. Relationship between LVMI, insulin sensitivity indices, and other
cardiovascular risk factors in obese children and in the MS group
Obese children  MS group 
rp  r   p  
Weight 0.201  <0.001  0.362  0.004 
Height 0.148  0.45  0.278  0.023 
BMI 0.190  0.009  0.347  0.006 
BMI-SDS 0.262  <0.001  0.360  0.005 
Systolic BP  0.443  <0.001  0.065  0.324 
Diastolic BP  0.436  <0.001  0.436  0.090 
Waist circumference  0.264  <0.001  0.216  0.062 
L Li ip pi id ds s
Triglycerides 0.399 <0.001  -0.067  0.319 
HDL cholesterol -0.261  <0.001  0.008 0.479 
Apo-A -0.223  0.015  -0.149  0.212 
Fasting insulin  0.367  <0.001  0.325  0.009 
FGIR 0.351  <0.001  0.311  0.013 
HOMA-IR 0.341  <0.001  0.319  0.010 
QUICK-I -0.278  <0.001  -0.331  0.008 
HOMA-IR: homeostasis model assessment of insulin resistance, QUICK-I: quantitative
insulin sensitivity check index, FGIR: fasting glucose to insulin ratio, LVMI: left 
ventricular mass index, BMI: body mass index, SDS: standard deviation score, 
MS: metabolic syndrome, HDL: high-density lipoprotein, BP: blood pressurechildren with obesity. Therefore, these data supported the idea
that insulin resistance may have a role in the development of
cardiac hypertrophy in obese children. 
In overweight adults, insulin resistance was linked to
increased LVM independent of BMI and BP. The method of
correcting LVM for body size and the criteria used to define
LVM have varied between studies (21,23). LVM has been
adjusted for height, body surface area, weight, and height
raised to various powers. Because of the rise in the prevalence
of obesity, indexing of LVM to weight or body surface area may
allow an increased LVM to be interpreted erroneously as 
normal (28). Height2.7 (in meters) has been validated as an 
indicator of lean body mass and has been recommended for
indexing LVM. Use of height2.7 to index LVM also minimizes
the effect of age, gender, and race (23,24). A clamp study of
adults showed no significant relationship between LVM and
insulin resistance when obesity, BP, sex, and age were 
covaried (28). However, the authors acknowledged that insulin
resistance may mediate the influence of obesity on cardiac
structure. Adjusting for obesity in studies of insulin resistance
may not be appropriate, because of its collinearity with insulin.
To our knowledge, this is the first study that gives the cut-off
level of LVMI in children and adolescents with MS. The present
LVMI cut-off point of 33g/m2 for the diagnosis of MS yielded a
sensitivity of 97% and a specificity of 98%.
A few pediatric studies have shown that LVM is related to
insulin resistance syndrome characteristics in youth. Cross-
sectional and longitudinal studies of normotensive young 
people (6-27 years old) have revealed that LVM is predicted by
adiposity and resting and challenge hemodynamics. Daniels et
al (24) reported that in children 9 to 17 years old, LVM was more
closely related to central fat than overall adiposity, and that 
central fat was associated with less favorable lipid and BP 
levels. Gutin et al (29) studied children 7 to 13 years old and
found LVM to be related to percent body fat and insulin levels.
The Bogalusa Heart Study reported an association between
fasting blood sugar and LVM in youth (13–27 years old) (30).
They showed that increased insulin levels predict greater LVM
in obese persons, independent of relations among insulin, 
obesity, and BP. 
Davis et al (30) examined clustering of insulin resistance
syndrome characteristics and LVMI in a sample of healthy
youths. LVMI was associated with higher fasting glucose,
hyperinsulinemia, and central adiposity, as shown by increased
waist girth. After accounting for contributions of race, gender,
and systolic BP, both insulin and waist girth independently 
predicted LVMI. A one-factor model of insulin resistance 
syndrome including insulin, glucose, waist girth, and LVMI
showed good fit to the data. 
These results show that an incipient cardiovascular risk 
syndrome is detectable even in healthy young people. Cardiac
structure seems to be as closely associated with this syndrome
as fasting glucose level. These relationships among central 
obesity, glycemia, hyperinsulinemia, and cardiac structure
found in healthy youths suggest that alterations in cardiac 
structure early in life may be part of the progression of insulin
resistance syndrome pathophysiology, with important 
implications for development of risk factors for hypertension,
T2DM, and atherosclerosis. In the present study, evaluation of
obese children showed that fasting glucose was not 
associated with LVMI, although fasting insulin was significantly
associated with LVMI. Therefore, these data supported the
idea that insulin resistance may have a role in the increasing
LVMI in children with obesity. In the present study, conducted
in a group of obese children, we found that insulin sensitivity
indices derived from fasting samples and elevated basal insulin
levels were significantly associated with increased LVMI. 
Many of the previous studies evaluating LVM in children
were performed in years prior to the dramatic increase which
occurred in prevalence of obesity (31). Hanevold et al (32)
found that the prevalence of LV hypertrophy in a multiethnic
group of children and adolescents with hypertension was
15.5% using adult criteria and 41.1% using pediatric criteria,
and that increasing BMI was associated with a higher LVMI.
However, this study suggested that LV hypertrophy occurs
commonly in children with hypertension and is associated
with an increased BMI. 
In conclusion, we think that our optimal LVMI cut-off value
for identifying MS may be a sensitive index in screening obese
children and adolescents with pediatric MS. We suggest that
assessment of LVMI in routine echocardiographic examinations
of obese children and adolescents might be used in predicting
the presence of MS and its associated cardiovascular risks. 
MS seems to increase LVM over and above the potential 
contribution of BP, body size and other single components of
this syndrome. Since LVM is a well-known predictor of 
cardiovascular events, our results may partly explain the
enhanced cardiovascular risk associated with MS.
Atabek ME et al.
Left Ventricular Mass Index in Metabolic Syndrome 
Figure 1. Cut-off points, sensitivity and specificity of LVMI according
to metabolic syndrome 
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